ArticleFrontiers in immunology2021
Anti-Angiogenic Efficacy of PSORI-CM02 and the Associated Mechanism in Psoriasis
Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 19 citations in OpenAlex.
- Multi-Target Anti-Psoriatic Effects ofMolecules (Basel, Switzerland) · 2026Article
- Role of dendritic cells and B cells in the skin of imiquimod (IMQ)-induced psoriasis-like mouse model.PeerJ · 2026Article
- The Therapeutic Potential ofInternational journal of molecular sciences · 2025Article
- Targeting psoriatic inflammation with natural compounds: mechanistic insights and therapeutic promise.Inflammopharmacology · 2025Review
- Psoriasis: A Multidimensional Review of Onset, Progression, Treatment, and the Evolution of Disease Models.Molecular diagnosis & therapy · 2025Review
- SB218078 inhibits angiogenesis and epithelial-mesenchymal transition in breast cancer.Frontiers in pharmacology · 2025Article
- PSORI-CM02 Restores Epidermal Differentiation in Psoriasis via the Gut Microbiota-Sphingolipid Axis.Drug design, development and therapy · 2025Article
- Examining the functions of the vascular endothelial growth factor/hypoxia-inducible factor signaling pathway in psoriatic arthritis.Archives of rheumatology · 2023Article
- Advances in the study of macrophage polarization in inflammatory immune skin diseases.Journal of inflammation (London, England) · 2023Review
- Chinese Medicine as Supporting Therapy for Psoriasis: Past, Present, and Future.Chinese journal of integrative medicine · 2023Review
- Deciphering the mechanism of PSORI-CM02 in suppressing keratinocyte proliferation through the mTOR/HK2/glycolysis axis.Frontiers in pharmacology · 2023Article
- The Gene Expression Analysis of Peripheral Blood Monocytes From Psoriasis Vulgaris Patients With Different Traditional Chinese Medicine Syndromes.Frontiers in pharmacology · 2021Article
- Article
- Recent Update on Immunopathogenesis of Psoriasis.Indian journal of dermatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis is a chronic proliferative autoimmune dermatologic disease characterised by abnormal angiogenesis. Thus, regulating angiogenesis in the skin is an important treatment strategy for psoriasis. PSORI-CM02, an empirical Chinese medicine formula optimised from Yin Xie Ling, was created by the Chinese medicine specialist, Guo-Wei Xuan. Clinical studies have shown that PSORI-CM02 is safe and effective for the treatment of psoriasis. However, its anti-psoriatic mechanisms remain to be further explored. In this study, we investigated the effects of PSORI-CM02 on angiogenesis in the skin and the underlying mechanisms in IL-17A-stimulated human umbilical vein endothelial cells (HUVECs) and a murine model of imiquimod (IMQ)-induced psoriasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.